ZEAL Zealand Pharma A/S

31.21USD212.70 DKK · CPH-4.06%Mkt Cap: 2.07B USDP/E: 4.82

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on …

Institutional holders11 on file

Key Statistics

Company
Market Cap2.07B USD
Enterprise Value174.81M USD
Revenue (TTM)674.69M USD
Gross Profit1.35B USD
Net Income (TTM)947.21M USD
Revenue/Share9.65 USD
Last Price31.21 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees605
CountryDK
SectorHealthcare
IndustryBiotechnology
ISINDK0060257814
Valuation
P/E (Trailing)4.82
P/E (Forward)29.45
PEG—
EV/EBITDA0.44
EV/Revenue0.26
P/S3.07
P/B0.82
EPS (TTM)6.47 USD
EPS (Forward)1.06 USD
52W Range
31.210% of range81.59
52W High81.59 USD
52W Low31.21 USD
Profitability
Gross Margin99.99%
Oper. Margin59.03%
EBITDA Margin59.48%
Profit Margin70.05%
ROE43.52%
ROA40.47%
ROIC—
ROCE46.54%
Growth
Revenue Growth-92.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF958.50M USD
CapEx (TTM)10.14M USD
FCF Margin-36.76%
FCF Yield-11.98%
Net Debt-1.91B USD
Net Debt/EBITDA-4.76
Net Debt/FCF—
Balance Sheet
Debt/Equity0.03
Current Ratio10.50
Quick Ratio10.36
Book Value/Sh37.84 USD
Cash/Share29.66 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.4 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)56.29 USD
Upside (mean)+80.3%
Target Range41.09 USD – 80.71 USD
41.09+80.3% to mean80.71
# Analysts12
Ownership
Shares Out.66.33M
Float57.03M
Insiders0.53%
Institutions38.36%
Technical
SMA 5036.47 (-14.4%)
SMA 20043.42 (-28.1%)
Beta0.47
S&P 52W Chg12.00%
Avg Vol (30d)370.81K
Avg Vol (10d)446.12K
Technical Indicators
RSI (14)30.4
MACD-4.9999
MACD Signal-4.0238
MACD Hist.-0.9760
BB Upper36.91 USD
BB Middle34.26 USD
BB Lower31.61 USD
BB Width15.46%
ATR (14)1.305 USD
Vol Ratio (20d)1.64x

About Zealand Pharma (CPH: ZEAL)

›

Zealand Pharma (CPH: ZEAL) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 605 employees.

The shares were at 212.70 DKK on 19 November 2026, down 51.2% over 52 weeks. Its 52-week range is 212.70 DKK to 556.00 DKK, and it trades at the bottom of that range.

At a market capitalisation of 14.11B DKK, it trades at 4.8 times trailing earnings and 29.4 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 86% for ZEAL.

Zealand Pharma reports return on equity of 43.5%, an operating margin of 59.0% and revenue down 92.0% year over year.

It holds more cash than debt, a net cash position of 13.03B DKK. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 12 analysts cover the stock, with an average rating of Buy; their mean price target of 383.58 DKK is 80.3% above the current price. The next earnings report is expected on 25 February 2027.